Volume 10, Number 5—May 2004
Research
Multidrug-resistant Tuberculosis in Central Asia
Helen Suzanne Cox*
, Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶
, Juan Daniel Orozco*, Roy Male*, Sabine Ruesch-Gerdes†, Dennis Falzon*, Ian Small*, Darebay Doshetov‡, Yared Kebede§, and Mohammed Aziz¶Table 4
Second-line drug resistance resultsa
| New | Retreatment | MDR-TBb | ||||
|---|---|---|---|---|---|---|
| Total | Resistant (%) | Total | Resistant (%) | Total | Resistant (%) | |
| Karakalpakstan (Uzbekistan) | ||||||
| Prothionamide | 106 | 7 (7) | 107 | 11 (10) | 57 | 9 (16) |
| Capreomycin | 88 | 1 (1) | 101 | 1 (1) | 56 | 1 (2) |
| Ofloxacin | 88 | 2 (2) | 101 | 4 (4) | 56 | 1 (2) |
| Dashoguz (Turkmenistan) | ||||||
| Prothionamide | 105 | 1 (1) | 98 | 4 (4) | 22 | 2 (9) |
| Capreomycin | 89 | 0 | 93 | 0 | 21 | 0 |
| Ofloxacin | 89 | 0 | 93 | 0 | 21 | 0 |
aAll strains were tested for prothionamide; a representative subset of these were tested for both capreomycin and ofloxacin.
bMDR-TB, multidrug-resistant tuberculosis.
